Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
Crossref DOI link: https://doi.org/10.1007/s00296-016-3444-0
Published Online: 2016-02-27
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mysler, Eduardo
Pineda, Carlos
Horiuchi, Takahiko
Singh, Ena
Mahgoub, Ehab
Coindreau, Javier
Jacobs, Ira
Funding for this research was provided by:
Pfizer
License valid from 2016-02-27